73 related articles for article (PubMed ID: 14635084)
1. Imatinib mesylate causes hypopigmentation in the skin.
Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
[TBL] [Abstract][Full Text] [Related]
2. Fractional non-ablative assisted bimatoprost delivery: A synergistic approach for treating post-inflammatory hypopigmentation following cosmetic procedures in skin of color patients.
Jablon K; Theisen E; Hsu SH; Dover JS; Chung HJ
Lasers Surg Med; 2024 Jan; 56(1):11-13. PubMed ID: 38018657
[No Abstract] [Full Text] [Related]
3. A new hypothesis: imatinib affects leukemic stem cells in the same way it affects all other leukemic cells.
Tomasetti C
Blood Cancer J; 2011 May; 1(5):e19. PubMed ID: 22829154
[No Abstract] [Full Text] [Related]
4. Hypertriglyceridemia secondary to obesity and diabetes.
Subramanian S; Chait A
Biochim Biophys Acta; 2012 May; 1821(5):819-25. PubMed ID: 22005032
[TBL] [Abstract][Full Text] [Related]
5. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.
Apperley JF
Lancet Oncol; 2007 Nov; 8(11):1018-29. PubMed ID: 17976612
[TBL] [Abstract][Full Text] [Related]
6. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol.
Wiertz EJ; Jones TR; Sun L; Bogyo M; Geuze HJ; Ploegh HL
Cell; 1996 Mar; 84(5):769-79. PubMed ID: 8625414
[TBL] [Abstract][Full Text] [Related]
7. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.
Aleem A
Hematol Oncol Stem Cell Ther; 2009; 2(2):358-61. PubMed ID: 20118061
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate causes hypopigmentation in the skin.
Leong KW; Lee TC; Goh AS
Cancer; 2004 Jun; 100(11):2486-7; author reply 2487-8. PubMed ID: 15160360
[No Abstract] [Full Text] [Related]
9. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM; Hughes TP; Larson RA; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Boquimpani C; Pasquini R; Clark RE; Dubruille V; Flinn IW; Kyrcz-Krzemien S; Medras E; Zanichelli M; Bendit I; Cacciatore S; Titorenko K; Aimone P; Saglio G; Hochhaus A
Leukemia; 2021 Feb; 35(2):440-453. PubMed ID: 33414482
[TBL] [Abstract][Full Text] [Related]
10. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre PD; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Lustgarten S; Rivera VM; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes TP; Shah NP; Kantarjian HM
Blood; 2018 Jul; 132(4):393-404. PubMed ID: 29567798
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A; Larson RA; Guilhot F; Radich JP; Branford S; Hughes TP; Baccarani M; Deininger MW; Cervantes F; Fujihara S; Ortmann CE; Menssen HD; Kantarjian H; O'Brien SG; Druker BJ;
N Engl J Med; 2017 Mar; 376(10):917-927. PubMed ID: 28273028
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.
Dahlén T; Edgren G; Lambe M; Höglund M; Björkholm M; Sandin F; Själander A; Richter J; Olsson-Strömberg U; Ohm L; Bäck M; Stenke L;
Ann Intern Med; 2016 Aug; 165(3):161-6. PubMed ID: 27295519
[TBL] [Abstract][Full Text] [Related]
14. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Hochhaus A; Saglio G; Hughes TP; Larson RA; Kim DW; Issaragrisil S; le Coutre PD; Etienne G; Dorlhiac-Llacer PE; Clark RE; Flinn IW; Nakamae H; Donohue B; Deng W; Dalal D; Menssen HD; Kantarjian HM
Leukemia; 2016 May; 30(5):1044-54. PubMed ID: 26837842
[TBL] [Abstract][Full Text] [Related]
15. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Saussele S; Krauss MP; Hehlmann R; Lauseker M; Proetel U; Kalmanti L; Hanfstein B; Fabarius A; Kraemer D; Berdel WE; Bentz M; Staib P; de Wit M; Wernli M; Zettl F; Hebart HF; Hahn M; Heymanns J; Schmidt-Wolf I; Schmitz N; Eckart MJ; Gassmann W; Bartholomäus A; Pezzutto A; Leibundgut EO; Heim D; Krause SW; Burchert A; Hofmann WK; Hasford J; Hochhaus A; Pfirrmann M; Müller MC;
Blood; 2015 Jul; 126(1):42-9. PubMed ID: 25918346
[TBL] [Abstract][Full Text] [Related]
16. Altered bone and mineral metabolism in patients receiving imatinib mesylate.
Berman E; Nicolaides M; Maki RG; Fleisher M; Chanel S; Scheu K; Wilson BA; Heller G; Sauter NP
N Engl J Med; 2006 May; 354(19):2006-13. PubMed ID: 16687713
[TBL] [Abstract][Full Text] [Related]
17. Anticancer treatments and photosensitivity.
Sibaud V
J Eur Acad Dermatol Venereol; 2022 Jun; 36 Suppl 6(Suppl 6):51-58. PubMed ID: 35738806
[TBL] [Abstract][Full Text] [Related]
18. Topical therapy for regression and melanoma prevention of congenital giant nevi.
Choi YS; Erlich TH; von Franque M; Rachmin I; Flesher JL; Schiferle EB; Zhang Y; Pereira da Silva M; Jiang A; Dobry AS; Su M; Germana S; Lacher S; Freund O; Feder E; Cortez JL; Ryu S; Babila Propp T; Samuels YL; Zakka LR; Azin M; Burd CE; Sharpless NE; Liu XS; Meyer C; Austen WG; Bojovic B; Cetrulo CL; Mihm MC; Hoon DS; Demehri S; Hawryluk EB; Fisher DE
Cell; 2022 Jun; 185(12):2071-2085.e12. PubMed ID: 35561684
[TBL] [Abstract][Full Text] [Related]
19. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.
Kumar V; Singh P; Gupta SK; Ali V; Verma M
Mol Cell Biochem; 2022 Apr; 477(4):1261-1279. PubMed ID: 35129779
[TBL] [Abstract][Full Text] [Related]
20. Pyoderma gangrenosum-like necrotizing panniculitis associated with Imatinib: A case report.
Hernández J; Sanz A; Isla-Tejera B; Ruano J
Dermatol Reports; 2020 Jun; 12(1):8381. PubMed ID: 32685125
[No Abstract] [Full Text] [Related]
[Next] [New Search]
